… This review provides an introduction to the role of EGFR in lung cancer … EGFR tyrosine
kinase inhibitors and the subsequent discovery of EGFR mutations in non-small cell lung cancers …

… (EGFR) is a receptor tyrosine kinase which belongs to the EGFR family, consisting of four
members: EGFR, … the tyrosine kinase activity of EGFR via homo- or heterodimerization with …

… Among patients with non-small cell lung cancer (NSCLC), EGFR mutations, 90% of …
EGFR-tyrosine kinase inhibitor (TKI) therapies for EGFR-TKI-naïve NSCLC patients harboring EGFR …

… cancer (NSCLC). The availability of agents that target epidermal growth factor receptor (EGFR)-tyrosine …
In this report, we review the clinical data on the use of EGFR-tyrosine kinase …

… of the successes in targeting oncogene addiction in cancer and the role of tumor-… tyrosine
kinase inhibitor, which was granted full FDA approval in March 2017 based on targeting EGFR …

… adenocarcinoma and in smokers, are associated with resistance to EGFR tyrosine kinase
inhibitors (TKI). EGFR gene mutations are not found in tumors with K-RAS gene mutations. …

… (EGFR) tyrosine kinase inhibitors (TKIs) after surgery in patients with EGFR-mutant non-small
cell lung cancer (… previous one and presents our latest updates through the past few years. …

… EGFR TKIs, binding competitively and reversibly to the ATP-binding site of the EGFR
tyrosine … in outcome for NSCLC patients with activating EGFR mutations (L858R and Del19). …

… Currently available EGFR/HER2 tyrosine kinase inhibitors (TKIs) exhibit many adverse …
of breast cancer and its therapy. It emphasizes the currently marketed drugs for EGFR, HER2, …

… (EGFR) is a receptor tyrosine kinase of the ErbB receptor family that is abnormally activated
in many epithelial tumors. The aberrant activation of the EGFR … classes of anti-EGFR agents: …